{"nctId":"NCT03941964","briefTitle":"A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy","startDateStruct":{"date":"2019-08-15","type":"ACTUAL"},"conditions":["Acute Myeloid Leukemia (AML)","Cancer"],"count":60,"armGroups":[{"label":"Venetoclax 400 mg + azacitidine 75 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Venetoclax","Drug: Azacitidine"]},{"label":"Venetoclax 400 mg + decitabine 20 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Venetoclax","Drug: Decitabine"]}],"interventions":[{"name":"Venetoclax","otherNames":["ABT-199","VENCLEXTA","VENCLYXTO"]},{"name":"Azacitidine","otherNames":["Vidaza"]},{"name":"Decitabine","otherNames":["Dacogen"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participant has confirmation of acute myeloid leukemia (AML) by World Health Organization (WHO) criteria\n* Participant is deemed by the investigator to be an appropriate candidate for outpatient ramp-up of venetoclax\n* Participant is not eligible to receive treatment with standard cytarabine and anthracycline induction regimens\n* Participant has not received prior treatment for AML (treatment naïve) with the exception of hydroxyurea\n* Participant has no evidence of spontaneous tumor lysis syndrome (TLS) at Screening\n* Participant can have progressed from myelodysplastic syndrome (MDS) or be considered to have secondary AML and could have been treated with growth factors or other agents with the exception of hypomethylating agents\n* Participant has adequate kidney, liver, and hematology laboratory values as detailed in the protocol\n* Has an Eastern Cooperative Oncology Group (ECOG) Performance status of 0 to 3\n\nExclusion Criteria:\n\nHas a history of the following conditions:\n\n* Acute promyelocytic leukemia\n* Known active central nervous system involvement with AML\n* Positive for HIV (HIV testing is not required)\n* Positive for hepatitis B or C infection with the exception of those with an undetectable viral load within 3 months\n* Cardiovascular disability status of New York Heart Association Class \\> 2\n* Chronic respiratory disease that requires continuous oxygen or any other medical condition that in the opinion of the investigator would adversely affect his/her participating in this study\n* Malabsorption syndrome or other condition that precludes enteral route of administration\n\nHas a history of other malignancies within 2 years prior to study entry, with the exception of:\n\n* Adequately treated in situ carcinoma of the cervix uteri or carcinoma in situ of breast\n* Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin\n* Previous malignancy confined and surgically resected (or treated with other modalities) with curative intent","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Complete Remission or Complete Remission With Incomplete Blood Count Recovery (CR + CRi)","description":"The composite complete remission rate is defined as the percentage of participants with complete remission (CR) or complete remission with incomplete blood count recovery (CRi) at any time during the study as assessed by the investigator. Response was based on bone marrow results and hematology values according to the modified International Working Group (IWG) criteria for AML:\n\nCR: Absolute neutrophil count (ANC) \\> 10\\^3/μL (1,000/μL), platelets \\> 10\\^5/μL (100,000/μL), red blood cell (RBC) transfusion independence, and bone marrow with \\< 5% blasts\n\nCRi: Bone marrow with \\< 5% blasts, and absolute neutrophils of ≤ 10\\^3/μL or platelets ≤ 10\\^5/μL","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.0","spread":null},{"groupId":"OG001","value":"63.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Complete Remission (CR)","description":"The complete remission rate is defined as the percentage of participants with complete remission (CR) at any time during the study as assessed by the investigator. Response was based on bone marrow results and hematology values according to the modified International Working Group (IWG) criteria for AML:\n\nCR: Absolute neutrophil count (ANC) \\> 10\\^3/μL (1,000/μL), platelets \\> 10\\^5/μL (100,000/μL), red blood cell (RBC) transfusion independence, and bone marrow with \\< 5% blasts","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.3","spread":null},{"groupId":"OG001","value":"26.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Complete Remission With Incomplete Blood Count Recovery (CRi)","description":"The complete remission with incomplete blood count recovery rate is defined as the percentage of participants with complete remission with incomplete blood count recovery (CRi) at any time during the study as assessed by the investigator. Response was based on bone marrow results and hematology values according to the modified International Working Group (IWG) criteria for AML:\n\nCRi: Bone marrow with \\< 5% blasts, and absolute neutrophils of ≤ 10\\^3/μL or platelets ≤ 10\\^5/μL.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.7","spread":null},{"groupId":"OG001","value":"36.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Post-baseline Transfusion Independence","description":"The transfusion independence rate is defined as the percentage of participants with post-baseline transfusion independence, which is defined as a period of at least 56 days with no transfusion after the first dose of study drug and within 30 days of the last dose of study drug, death, or initiation of post-treatment therapy, whichever is earliest.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null},{"groupId":"OG001","value":"60.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.3","spread":null},{"groupId":"OG001","value":"73.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null},{"groupId":"OG001","value":"60.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":19,"n":30},"commonTop":["ANAEMIA","NEUTROPHIL COUNT DECREASED","NAUSEA","WHITE BLOOD CELL COUNT DECREASED","PLATELET COUNT DECREASED"]}}}